Personalized Drug Therapy in Oncology: Clinical Insights and Future Perspectives
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i1.3713
Abstract
Cancer treatment has made progress through personalized medical therapies that tailor strategies based on patient characteristics. This article explores the application of personalized therapies in oncology, including biomarker-guided therapies, liquid biopsies, next-generation sequencing, personalized immunotherapy, and nanotechnology-based drug delivery. Focusing on personalized drug therapy in oncology, this article delves into its clinical application. It elaborates on the use of biomarkers to guide medication, liquid biopsy for auxiliary diagnosis, and personalized immunotherapy, showcasing their role in advancing precision medicine. At the same time, it discusses the challenges faced in this field, such as high costs and complex data processing, and looks forward to the future prospects of personalized drug therapy in oncology. Despite advancements, challenges such as high costs and complex data analysis issues still persist.
Keywords
oncology; personalized drug therapy; genetic factors; physiological state; biomarker-guided therapy
Full Text
PDF - Viewed/Downloaded: 3 TimesReferences
[1] Mok et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 361(10), 947-957.
[2] Solomon et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine, 371(23), 2167-2177.
[3] Ledermann et al. (2012). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a pre-planned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology, 13(10), 111-118.
[2] Solomon et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine, 371(23), 2167-2177.
[3] Ledermann et al. (2012). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a pre-planned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology, 13(10), 111-118.
Copyright © 2025 Changxuan Liang

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License